NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
55513-0224-01 | 55513-0224 | Rituximab-arrx | Riabni | 100.0 mg/10mL | Immunotherapy | Monoclonal Antibody | CD20 | Intravenous | Jan 6, 2021 | In Use | |
00002-7669-01 | 00002-7669 | Ramucirumab | Cyramza | 10.0 mg/mL | Immunotherapy | Monoclonal Antibody | VEGF | Intravenous | Apr 21, 2014 | In Use | |
55513-0224-21 | 55513-0224 | Rituximab-arrx | Riabni | 100.0 mg/10mL | Immunotherapy | Monoclonal Antibody | CD20 | Intravenous | Jul 21, 2025 | In Use | |
50242-0918-01 | 50242-0918 | Atezolizumab | TECENTRIQ | 840.0 mg/14mL | Immunotherapy | Checkpoint Inhibitor | PD-L1 | Intravenous | Mar 8, 2019 | In Use | |
00085-1388-01 | 00085-1388 | Peginterferon alfa-2b | Sylatron | Immunotherapy | Cytokine | Interferon | Mar 29, 2011 | Jan 13, 2016 | No Longer Used | ||
59572-0410-28 | 59572-0410 | Lenalidomide | Revlimid | 10.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 3, 2009 | In Use | |
72893-0016-02 | 72893-0016 | Efbemalenograstim alfa-vuxw | RYZNEUTA | 20.0 mg/mL | Immunotherapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Subcutaneous | Nov 23, 2023 | In Use | |
55513-0206-01 | 55513-0206 | Bevacizumab-awwb | MVASI | 100.0 mg/4mL, 100.0 mg/4mL | Immunotherapy | Monoclonal Antibody | VEGFR | Intravenous | Jun 1, 2018 | In Use | |
61755-0008-01 | 61755-0008 | cemiplimab-rwlc | LIBTAYO | 50.0 mg/mL | Immunotherapy | Checkpoint Inhibitor | PD-1 | Intravenous | Sep 28, 2018 | In Use | |
00085-1287-03 | 00085-1287 | Peginterferon alfa-2b | Sylatron | Immunotherapy | Cytokine | Interferon | Mar 29, 2011 | Jan 13, 2016 | No Longer Used | ||
00074-1055-01 | 00074-1055 | Telisotuzumab Vedotin | EMRELIS | 100.0 mg/mL | Immunotherapy | Drug Antibody Conjugate | c-MET | Intravenous | May 14, 2025 | In Use | |
00480-1242-28 | 00480-1242 | Lenalidomide | Lenalidomide | 5.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 3, 2022 | In Use | |
72606-0037-01 | 72606-0037 | Denosumab-bmwo | Stoboclo | 60.0 mg/mL | Immunotherapy | Monoclonal Antibody | RANKL | Subcutaneous | Jul 2, 2025 | In Use | |
00115-1476-59 | 00115-1476 | Imiquimod | Imiquimod | 50.0 mg/g | Immunotherapy | Immunomodulator | Dermatological Agent | Topical | Feb 28, 2011 | Jun 1, 2017 | No Longer Used |
50242-0260-01 | 50242-0260 | Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf | Phesgo | 20000.0 U/10mL, 600.0 mg/10mL, 600.0 mg/10mL | Immunotherapy | Monoclonal Antibody | HER2 | Subcutaneous | Jun 29, 2020 | In Use | |
55513-0326-21 | 55513-0326 | rituximab-arrx | Riabni | 500.0 mg/50mL | Immunotherapy | Monoclonal Antibody | CD20 | Intravenous | Jul 21, 2025 | In Use | |
80739-0812-12 | 80739-0812 | Adagrasib | KRAZATI | 200.0 mg/1 | Immunotherapy | RAS Inhibitor | KRAS G12C | Oral | Dec 12, 2022 | In Use | |
73153-0900-01 | 73153-0900 | Lisocabtagene maraleucel | BREYANZI | Immunotherapy | CAR-T | CD19 | Feb 5, 2021 | In Use | |||
55513-0164-01 | 55513-0164 | Traztuzumab-anns, trastuzumab-anns | Kanjinti | Immunotherapy | Monoclonal Antibody | HER2 | Intravenous | Feb 1, 2023 | Jun 30, 2025 | No Longer Used | |
59572-0503-21 | 59572-0503 | Pomalidomide | Pomalyst | 3.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Feb 18, 2013 | In Use | |
55513-0326-01 | 55513-0326 | rituximab-arrx | Riabni | 500.0 mg/50mL | Immunotherapy | Monoclonal Antibody | CD20 | Intravenous | Jan 6, 2021 | In Use | |
55566-1050-01 | 55566-1050 | Nadofaragene firadenovec-vncg | ADSTILADRIN | 300000000000.0 {VP}/mL | Immunotherapy | Gene Therapy | IFN⍺2b | Intravesical | Jul 1, 2023 | In Use | |
00024-0656-01 | 00024-0656 | Isatuximab | Sarclisa | 500.0 mg/25mL | Immunotherapy | Monoclonal Antibody | CD38 | Intravenous | Mar 2, 2020 | In Use | |
00480-1246-21 | 00480-1246 | Lenalidomide | Lenalidomide | 25.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 3, 2022 | In Use | |
72187-0401-01 | 72187-0401 | Tagraxofusp | Elzonris | 1000.0 ug/mL | Immunotherapy | Fusion Protein | IL3/ CD123 | Intravenous | Jan 18, 2019 | In Use |
Found 11765 results — Export these results